Hanmi Science Co., Ltd.

KSE 008930.KS

Hanmi Science Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 1.41

Hanmi Science Co., Ltd. Price to Sales Ratio (P/S) is 1.41 on January 14, 2025, a -40.06% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Hanmi Science Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 3.01 on January 16, 2024, which is 113.67% above the current Price to Sales Ratio (P/S).
  • Hanmi Science Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 1.38 on January 10, 2025, which is -2.04% below the current Price to Sales Ratio (P/S).
  • Hanmi Science Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 1.82.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
KSE: 008930.KS

Hanmi Science Co., Ltd.

CEO Mr. Jong-Hoon Lim
IPO Date Sept. 29, 2005
Location South Korea
Headquarters 14, Wiryeseong-daero
Employees 402
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is based in Seoul, South Korea.

StockViz Staff

January 15, 2025

Any question? Send us an email